A retrospective study of serum KL-6 levels during treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: a report from the Ad Hoc Committee for Safety of Biological DMARDs of the Japan College of Rheumatology

2013 ◽  
Vol 23 (2) ◽  
pp. 297-303 ◽  
Author(s):  
Akito Takamura ◽  
Shintaro Hirata ◽  
Hayato Nagasawa ◽  
Hideto Kameda ◽  
Yohei Seto ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Retrospective Study ◽  
Ad Hoc ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Biological Dmards ◽  
Disease Modifying

The 2018 OMERACT Synovial Tissue Biopsy Special Interest Group Report on Standardization of Synovial Biopsy Analysis

2019 ◽  
Vol 46 (10) ◽  
pp. 1365-1368 ◽  
Author(s):  
Mihir D. Wechalekar ◽  
Aurélie Najm ◽  
Douglas J. Veale ◽  
Vibeke Strand
Keyword(s):  
Rheumatoid Arthritis ◽  
Retrospective Study ◽  
Synovial Tissue ◽  
Multicenter Study ◽  
Delphi Survey ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Tissue Biopsy ◽  
Group Report ◽  
Disease Modifying

Objective.The Outcome Measures in Rheumatology (OMERACT) synovial tissue biopsy (STB) working group initiated an international effort to standardize STB analyses, define consensual items to inform treatment choices, and predict responses in rheumatoid arthritis (RA).Methods.(1) A Delphi survey to determine items for STB analyses. (2) A multicenter retrospective study of STB data in patients with RA posttreatment with biological disease-modifying antirheumatic drugs.Results.The Delphi survey identified 18 STB analyses items. Consensus on histological markers was achieved in the OMERACT 2018 SIG.Conclusion.Six markers were identified for examination in a multicenter study designed to define an OMERACT-endorsed set of STB markers to predict responses to treatment.

Incidence and factors related to SARS-CoV-2 infection in a cohort of patients with rheumatoid arthritis in Colombia during the COVID-19 pandemic v1

2021 ◽  
Author(s):  
Jorge Machado Alba
Keyword(s):  
Rheumatoid Arthritis ◽  
Diabetes Mellitus ◽  
Treatment Strategies ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Biological Dmards ◽  
Increased Risk ◽  
Systemic Glucocorticoids ◽  
Synthetic Dmards ◽  
Disease Modifying

Introduction:Patients with rheumatoid arthritis (RA) have an increased risk of SARS-CoV-2 infection due to intrinsic characteristics of the pathology and the medications used to treat it. Objective: To evaluate the incidence of and factors related to SARS-CoV-2 infection in patients with RA in Colombia. Materials and methods: This was an observational study of patients diagnosed with RA who were treated at a health care institution in Colombia. The study evaluated whether the patients presented SARS-CoV-2 infection and other clinical variables. Variables associated with the risk of SARS-CoV-2 infection were identified. Results: A total of 2,566 patients with RA were identified. They had a median age of 61.9 years, and 81.1% were women. They were mainly treated with synthetic disease-modifying antirheumatic drugs (DMARDs) (85.3%), glucocorticoids (52.2%) and biological DMARDs (26.8%). The incidence of SARS-CoV-2 infection was 5.1%, and the factors that increased the risk included treatment with synthetic DMARDs with or without biological DMARDs but with concomitant systemic glucocorticoids (OR: 2.18, 95% CI: 1.21-3.93 and OR: 1.69, 95% CI: 1.05-2.74, respectively) and receiving antidiabetic drugs (OR: 2.24, 95% CI: 1.27-3.94). A total of 20.8% of patients with COVID-19 required hospitalization, and 3.8% died. Conclusions: The incidence of COVID-19 is higher among patients with RA who receive DMARDs and glucocorticoids simultaneously or who have diabetes mellitus than among RA patients not receiving these drug combinations, which should guide treatment strategies.

scholarly journals Profil de la polyarthrite rhumatoïde en consultation rhumatologique à Lomé (Togo)

2017 ◽  
Vol 13 (15) ◽  
pp. 125 ◽  
Author(s):  
Kakpovi K. ◽  
Koffi-Tessio V. ◽  
Houzou P. ◽  
Fianyo E. ◽  
Kolou M. ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Retrospective Study ◽  
Rheumatoid Factor ◽  
Median Duration ◽  
Carpal Bones ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Polyarthrite Rhumatoïde ◽  
The Mean ◽  
Disease Modifying

Objective: To determine epidemiological, clinical, therapeutic aspects and outcomes of rheumatoid arthritis (RA) in rheumatologic consultation at lome (Togo). Patients and method: This was retrospective study carried out from 1 stJanuary 1990 to 31 stDecember 2015 in the rheumatology department. The study included all patients suffered from RA in rheumatologic consultations and who fulfilled the 2010 ACR and EULAR’s criteria. Results: Ninety two (77 women and 15 men) out of 25.992 patients (0.3%) examined in 25 years had suffered from RA. The mean age at admission was 42 years (range: 17-82 years). The median duration of the diseases was four years (range: 14days – 20 days). The diseases onset was polyarticular with 86% of the patients and oligoarticular with the thirteen others (14%). The proximal interphalangeal (PIP) joints and metacarpophalangeal (MCP) joints are involved in 81,5 % of cases; and the wrists in 77,2% of cases. The rheumatoid hip was observed in four patients. Forty-two of the patients (45,6%) presented RA deformities. Bilateral MCP and IPP joint early erosion was observed in 36 patients (39,1%) and bilateral carpal diffuse osteoporosis in 44 patients (47,8%). The ankylosis of the carpal bones was observed in 26 patients (28,2 %). Rheumatoid factor was positive in 44% of patients. Methotrexate was the most commonly disease-modifying antirheumatic drugs used in 44,4% of the patients. The disease was improved in 89% of patients. Conclusion: Rheumatoid arthritis seems relatively rare in Togo. It’s diagnosis is often made at the established phase and methotrexate remains the cornerstone of the treatment.

scholarly journals FRI0526 THE INCIDENCE, PREVALENCE AND MEDICATION USE OF RHEUMATOID ARTHRITIS AMONG KOREAN WOMEN IN CHILDBEARING YEARS: A NATIONWIDE POPULATION-BASED STUDY

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 862.2-863
Author(s):  
M. K. Chung ◽  
J. S. Park ◽  
H. S. Lim ◽  
C. H. Lee ◽  
J. Lee
Keyword(s):  
Rheumatoid Arthritis ◽  
Lupus Erythematosus ◽  
Medication Use ◽  
Population Based ◽  
Korean Women ◽  
Childbearing Age ◽  
Disease Modifying Antirheumatic Drugs ◽  
Antirheumatic Drugs ◽  
Disease Modifying ◽  
Incidence Prevalence

Background:Rheumatoid arthritis (RA) predominantly affects women and has a significant impact on childbearing. Several population-based studies identifying incidence, prevalence, and medication use of RA have been reported, yet epidemiological studies focusing on women with RA in childbearing years are missing.Objectives:We aimed to identify the incidence, prevalence and medication use of RA among Korean women in childbearing years.Methods:From National Health Insurance Service (NHIS) data (2009-2016), containing inpatient and outpatient claim information for approximately 97% of the Korean population, we identified 9,217,139 women aged between 20-44 years. Incidence and prevalence of RA in the specific sociodemographic group of women in childbearing age were analyzed, and the prevalence of medication prescription were compared between women with RA and controls without rheumatic diseases such as RA, systemic lupus erythematosus, and ankylosing spondylitis. Individuals with RA were defined by the presence of International Classification of Disease, 10th revision code, M05. The medication use was defined as receiving > 90days prescriptions of NSAIDs, corticosteroids (CSs), and conventional synthetic (cs) disease modifying antirheumatic drugs (DMARDs) or > 1day prescription of biologic (b) DMARDs.Results:Total 24,590 women with RA were identified. The average incidence of RA during 2011-2016 among women in childbearing years was 24.1/100,000 person-years (PYs) (95% CI 20.91-27.31) with a yearly increase from 20.99/100,000 PYs in 2011 to 28.38/100,000 PYs in 2016. The average prevalence of RA during 2009-2016 among women in childbearing years was 105.2/100,000 PYs (95% CI 99.0-111.5) with a minimum of 95.7/100,000 PYs in 2009 and a maximum of 110.5/100,000 PYs in 2016. There were increasing trends in both incidence and prevalence of RA according to age among women in childbearing years peaking in the age group of 40-44 years. The prescriptions of NSAIDs, CSs, csDMARDs and bDMARDs were more frequent in women with RA than controls (NSAIDs; 94.21% vs 21.79%, CSs; 83.65% vs 4.28%, csDMARDs; 91.23% vs 0.41%, bDMARDs; 0.11% vs 0%, p<0.001).Conclusion:The incidence and prevalence of RA are high among Korean women in childbearing years, and medication use was significantly more frequent in this specific population than controls. High disease burden is imposed upon women in childbearing years.References:[1] Won S, Cho SK, Kim D, Han M, Lee J, Jang EJ, Sung YK, Bae SC: Update on the prevalence and incidence of rheumatoid arthritis in Korea and an analysis of medical care and drug utilization. Rheumatol Int 2018, 38(4):649-656.[2] Smeele HTW, Dolhain R: Current perspectives on fertility, pregnancy and childbirth in patients with Rheumatoid Arthritis. Seminars in arthritis and rheumatism 2019, 49(3s):S32-s35.Table 1.Medication use among women with RA and controls in childbearing age between 20-44 years during 2009-2016Control(n=155,486)RA(n=23,756)n(%)n(%)PNSAIDs33,887(21.79)22,380(94.21)<.0001Steroids6,653(4.28)19,871(83.65)<.0001csDMARDs634(0.41)21,673(91.23)<.0001bDMARDs0(0.00)27(0.11)<.0001RA, rheumatoid arthritis; NSAID, non-steroidal anti-inflammatory drug; cs, conventional synthetic; b, biologic; DMARDs, disease modifying antirheumatic drugsDisclosure of Interests:None declared

Sign in / Sign up

Export Citation Format

Share Document